Bach Pharma Inc, Developing New Drug, GVT® to Treat Veterans Suffering from Gulf War Illness, and Millions of People Suffering from Neurodegenerative Diseases

Share Article

North Andover MA's Bach Pharma Inc. has developed a new drug GVT that has high hopes of treating Gulf War Illness and other neurodegenerative diseases. Now, the company is facing the challenge of competing with large pharma companies to get the drug released.

Bach Pharma, developing GVT

Bach Pharma Logo

What we experienced ... was just short of a miracle. We continue to witness the powerful benefits from these products every day.

Bach Pharma, Inc., a company based in North Andover, Massachusetts, is continuing its research and development of its drug platform GVT (Monosodium Luminol), created to treat and cure multiple neurodegenerative diseases including Gulf War Illness (GWI), ALS, and Parkinson’s disease among others. Overwhelming data from multiple animal studies have proven that GVT has the potential to help millions of people suffering from neurodegenerative diseases, specifically focusing on Veterans who suffer the effects of Gulf War Illness and related conditions.

In 2001, CEO Mark Henry, working with real estate developer Harold Brooks was able to recognize the immense potential for a drug platform they discovered while searching for drugs to help critically ill people survive. The major accomplishment for Henry was locating and bringing together eight founders were able to attract research institutions all over the world and convince them to work together to help mankind. While never intending to compete with the massive pharmaceutical corporations – the founders realized that this product, GVT, could make a huge difference to millions suffering the effects of Neurodegenerative Diseases. Henry recalls that, “What we experienced in the late 1990s was just short of a miracle. We continue to witness the powerful benefits from these products every day. With new data we discover new medical opportunities.”

Bach Pharma Inc’s primary medical product is GVT which is designed to act as a redox buffer in the patients’ brain cells – minimizing and potentially reversing the effects of Gulf War Illness in Veterans. As of 2019, it is believed that over 250,000 US Veterans suffer from some form of GWI and its associated complications including Parkinson’s disease and ALS.

Having successfully demonstrated effectiveness in several GWI animal models, Bach Pharma is in the midst of a $2.2M capital raise in order to fund the next stage of preclinical testing, specifically a toxicology study for the Veteran’s Administration. Individual Investors, Foundations and Veteran Organizations have already committed over $500,000 to this project. Once the toxicology studies are completed, Bach will qualify for an additional $8 million commitment from the US Department of Defense for additional testing of GVT.

COO Christopher LaFarge believes that GVT will be a safe and effective solution for the millions suffering from Neurodegenerative Diseases, “We have proven that neurodegenerative diseases, GWI, radiation exposure, and other related diseases share a common theme, namely oxidative stress, and that GVT has enormous potential to help millions live reasonably normal lives.”

About Bach Pharma, Inc.: Bach Pharma, Inc. (BACH), a privately held research and development pharmaceutical company, directs the development of therapies for degenerative neurological illnesses. The company’s lead candidate GVT is a novel cytoprotective agent that has powerful anti-oxidant and anti-inflammatory properties, which research has shown can reverse oxidative stress, restore intracellular redox homeostasis and quell inflammation. Due to its strong safety profile along with its ability to cross the retinal and the blood-brain barriers and enter cells of the central nervous system, GVT has the potential to treat serious diseases of the central nervous and immune systems and dramatically reduce the cost of global health care.
BACH is a proud member of the Massachusetts Biotechnology Council and a host company for the Massachusetts Life Science Center Internship Challenge.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jamie Jamitkowski

Jamie Jamitkowski
@BachPharma
since: 06/2019
Follow >
Bach Pharma
Like >
Visit website